TWI694074B - 作為組蛋白去乙醯酶６抑制劑之１,３,４-㗁二唑磺醯胺衍生物及含彼之醫藥組合物 - Google Patents
作為組蛋白去乙醯酶６抑制劑之１,３,４-㗁二唑磺醯胺衍生物及含彼之醫藥組合物 Download PDFInfo
- Publication number
- TWI694074B TWI694074B TW105123853A TW105123853A TWI694074B TW I694074 B TWI694074 B TW I694074B TW 105123853 A TW105123853 A TW 105123853A TW 105123853 A TW105123853 A TW 105123853A TW I694074 B TWI694074 B TW I694074B
- Authority
- TW
- Taiwan
- Prior art keywords
- methyl
- alkyl
- mmol
- sulfonamide
- reaction mixture
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 14
- -1 1,3,4-oxadiazole sulfamide derivative compounds Chemical class 0.000 title description 136
- 229940122617 Histone deacetylase 6 inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 238
- 150000003839 salts Chemical class 0.000 claims abstract description 56
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 48
- 201000010099 disease Diseases 0.000 claims abstract description 43
- 102000003964 Histone deacetylase Human genes 0.000 claims abstract description 22
- 108090000353 Histone deacetylase Proteins 0.000 claims abstract description 22
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 9
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 6
- 208000025966 Neurological disease Diseases 0.000 claims abstract description 6
- 230000001404 mediated effect Effects 0.000 claims abstract description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 4
- 206010008805 Chromosomal abnormalities Diseases 0.000 claims abstract description 4
- 208000031404 Chromosome Aberrations Diseases 0.000 claims abstract description 4
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 4
- 206010010356 Congenital anomaly Diseases 0.000 claims abstract description 4
- 230000003542 behavioural effect Effects 0.000 claims abstract description 4
- 208000010643 digestive system disease Diseases 0.000 claims abstract description 4
- 208000016097 disease of metabolism Diseases 0.000 claims abstract description 4
- 230000002124 endocrine Effects 0.000 claims abstract description 4
- 208000030172 endocrine system disease Diseases 0.000 claims abstract description 4
- 230000036244 malformation Effects 0.000 claims abstract description 4
- 230000003340 mental effect Effects 0.000 claims abstract description 4
- 210000002346 musculoskeletal system Anatomy 0.000 claims abstract description 4
- 208000023504 respiratory system disease Diseases 0.000 claims abstract description 4
- 210000002808 connective tissue Anatomy 0.000 claims abstract 2
- 206010033675 panniculitis Diseases 0.000 claims abstract 2
- 210000004304 subcutaneous tissue Anatomy 0.000 claims abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- BNYCHCAYYYRJSH-UHFFFAOYSA-N 1h-pyrazole-5-carboxamide Chemical class NC(=O)C1=CC=NN1 BNYCHCAYYYRJSH-UHFFFAOYSA-N 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 125000004434 sulfur atom Chemical group 0.000 claims description 5
- ZVXKYWHJBYIYNI-UHFFFAOYSA-N 1h-pyrazole-4-carboxamide Chemical class NC(=O)C=1C=NNC=1 ZVXKYWHJBYIYNI-UHFFFAOYSA-N 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 239000000203 mixture Substances 0.000 abstract description 68
- 108010023925 Histone Deacetylase 6 Proteins 0.000 abstract description 32
- 238000000034 method Methods 0.000 abstract description 22
- 230000002401 inhibitory effect Effects 0.000 abstract description 11
- 238000002360 preparation method Methods 0.000 abstract description 8
- 230000002265 prevention Effects 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 102000011427 Histone Deacetylase 6 Human genes 0.000 abstract 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 708
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 680
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 495
- 239000000243 solution Substances 0.000 description 386
- 239000011541 reaction mixture Substances 0.000 description 305
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 262
- 229920006395 saturated elastomer Polymers 0.000 description 241
- 235000019439 ethyl acetate Nutrition 0.000 description 227
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 214
- 238000000605 extraction Methods 0.000 description 192
- 239000012044 organic layer Substances 0.000 description 192
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 189
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 174
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 169
- 229910004298 SiO 2 Inorganic materials 0.000 description 161
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 147
- 239000007787 solid Substances 0.000 description 135
- 239000011780 sodium chloride Substances 0.000 description 131
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 126
- 238000004587 chromatography analysis Methods 0.000 description 123
- YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical compound COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 description 122
- 238000006243 chemical reaction Methods 0.000 description 119
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 100
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 84
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 83
- 235000017557 sodium bicarbonate Nutrition 0.000 description 83
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 78
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 77
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 74
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 68
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 64
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 60
- 230000002829 reductive effect Effects 0.000 description 56
- 239000002904 solvent Substances 0.000 description 56
- DWXLVZSMXXCSMJ-UHFFFAOYSA-N piperazine-1-sulfonamide Chemical compound NS(=O)(=O)N1CCNCC1 DWXLVZSMXXCSMJ-UHFFFAOYSA-N 0.000 description 55
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 54
- 238000001914 filtration Methods 0.000 description 53
- 239000002244 precipitate Substances 0.000 description 53
- 229940124530 sulfonamide Drugs 0.000 description 53
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 50
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 48
- IYXUFOCLMOXQSL-UHFFFAOYSA-N (2,2-difluoroacetyl) 2,2-difluoroacetate Chemical compound FC(F)C(=O)OC(=O)C(F)F IYXUFOCLMOXQSL-UHFFFAOYSA-N 0.000 description 46
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 46
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 39
- 238000000746 purification Methods 0.000 description 38
- 235000019270 ammonium chloride Nutrition 0.000 description 37
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 33
- 150000001335 aliphatic alkanes Chemical class 0.000 description 32
- 239000012043 crude product Substances 0.000 description 32
- 102100022537 Histone deacetylase 6 Human genes 0.000 description 29
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 28
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 24
- 238000003756 stirring Methods 0.000 description 22
- 230000008859 change Effects 0.000 description 21
- 230000000694 effects Effects 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- 238000010992 reflux Methods 0.000 description 20
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 18
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 18
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 18
- 239000012141 concentrate Substances 0.000 description 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 16
- 239000002253 acid Substances 0.000 description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 14
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 13
- 150000002148 esters Chemical class 0.000 description 13
- 229910000104 sodium hydride Inorganic materials 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 12
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 12
- 239000012312 sodium hydride Substances 0.000 description 12
- 239000002002 slurry Substances 0.000 description 11
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 11
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 10
- IRQSKJQDKUAART-UHFFFAOYSA-N methyl 6-(bromomethyl)pyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(CBr)N=C1 IRQSKJQDKUAART-UHFFFAOYSA-N 0.000 description 10
- 229940095102 methyl benzoate Drugs 0.000 description 10
- NYTDLUUDHUJBJW-UHFFFAOYSA-N piperazine-1-sulfonamide;hydrochloride Chemical compound Cl.NS(=O)(=O)N1CCNCC1 NYTDLUUDHUJBJW-UHFFFAOYSA-N 0.000 description 10
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 9
- WARCRYXKINZHGQ-UHFFFAOYSA-N benzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1 WARCRYXKINZHGQ-UHFFFAOYSA-N 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 239000012230 colorless oil Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 9
- 235000001968 nicotinic acid Nutrition 0.000 description 9
- 239000011664 nicotinic acid Substances 0.000 description 9
- 229960003512 nicotinic acid Drugs 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- ROADCYAOHVSOLQ-UHFFFAOYSA-N 3-oxetanone Chemical compound O=C1COC1 ROADCYAOHVSOLQ-UHFFFAOYSA-N 0.000 description 8
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 8
- 239000005711 Benzoic acid Substances 0.000 description 8
- 229930040373 Paraformaldehyde Natural products 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- 235000010233 benzoic acid Nutrition 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 8
- 229920002866 paraformaldehyde Polymers 0.000 description 8
- UTPSYBWCOVZREX-UHFFFAOYSA-N piperazine-1-sulfonamide dihydrochloride Chemical compound Cl.Cl.N1(CCNCC1)S(=O)(=O)N UTPSYBWCOVZREX-UHFFFAOYSA-N 0.000 description 8
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 8
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 7
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 7
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 7
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 7
- WNPFDMGMNSMOMD-UHFFFAOYSA-M 1-imidazol-1-ylsulfonyl-3-methylimidazol-3-ium;trifluoromethanesulfonate Chemical compound [O-]S(=O)(=O)C(F)(F)F.C1=[N+](C)C=CN1S(=O)(=O)N1C=NC=C1 WNPFDMGMNSMOMD-UHFFFAOYSA-M 0.000 description 6
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 6
- 239000012346 acetyl chloride Substances 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- 230000002194 synthesizing effect Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- SHQSVMDWKBRBGB-UHFFFAOYSA-N cyclobutanone Chemical compound O=C1CCC1 SHQSVMDWKBRBGB-UHFFFAOYSA-N 0.000 description 5
- LVYSVCVDBBEQEB-UHFFFAOYSA-N methyl 4-[(3-chloro-4-fluoro-N-piperazin-1-ylsulfonylanilino)methyl]benzoate hydrochloride Chemical compound Cl.COC(=O)c1ccc(CN(c2ccc(F)c(Cl)c2)S(=O)(=O)N2CCNCC2)cc1 LVYSVCVDBBEQEB-UHFFFAOYSA-N 0.000 description 5
- YRQCLNOYFTTWJY-UHFFFAOYSA-N methyl 4-[(N-[methyl(2-piperazin-1-ylethyl)sulfamoyl]anilino)methyl]benzoate Chemical class COC(=O)C1=CC=C(CN(C2=CC=CC=C2)S(=O)(=O)N(C)CCN2CCNCC2)C=C1 YRQCLNOYFTTWJY-UHFFFAOYSA-N 0.000 description 5
- QAFDOZLXNKUWCI-UHFFFAOYSA-N methyl 4-[(N-piperazin-1-ylsulfonylanilino)methyl]benzoate hydrochloride Chemical compound Cl.COC(=O)c1ccc(CN(c2ccccc2)S(=O)(=O)N2CCNCC2)cc1 QAFDOZLXNKUWCI-UHFFFAOYSA-N 0.000 description 5
- USBPOEAFLLEEHP-UHFFFAOYSA-N methyl 6-[(3-chloro-4-fluoro-N-piperazin-1-ylsulfonylanilino)methyl]pyridine-3-carboxylate hydrochloride Chemical compound Cl.COC(=O)c1ccc(CN(c2ccc(F)c(Cl)c2)S(=O)(=O)N2CCNCC2)nc1 USBPOEAFLLEEHP-UHFFFAOYSA-N 0.000 description 5
- 229940050176 methyl chloride Drugs 0.000 description 5
- OIRDBPQYVWXNSJ-UHFFFAOYSA-N methyl trifluoromethansulfonate Chemical compound COS(=O)(=O)C(F)(F)F OIRDBPQYVWXNSJ-UHFFFAOYSA-N 0.000 description 5
- 150000003335 secondary amines Chemical class 0.000 description 5
- 150000003456 sulfonamides Chemical class 0.000 description 5
- ASRHZFWROABGOC-UHFFFAOYSA-N thiomorpholine-4-sulfonamide Chemical compound NS(=O)(=O)N1CCSCC1 ASRHZFWROABGOC-UHFFFAOYSA-N 0.000 description 5
- 108010033040 Histones Proteins 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- QSNWHKSIIWBAFP-UHFFFAOYSA-N methyl 6-[(3-chloro-N-piperazin-1-ylsulfonylanilino)methyl]pyridine-3-carboxylate hydrochloride Chemical compound Cl.COC(=O)c1ccc(CN(c2cccc(Cl)c2)S(=O)(=O)N2CCNCC2)nc1 QSNWHKSIIWBAFP-UHFFFAOYSA-N 0.000 description 4
- XPZLXLGSSXJCGG-UHFFFAOYSA-N methyl 6-[(N-piperazin-1-ylsulfonylanilino)methyl]pyridine-3-carboxylate dihydrochloride Chemical compound Cl.Cl.COC(=O)c1ccc(CN(c2ccccc2)S(=O)(=O)N2CCNCC2)nc1 XPZLXLGSSXJCGG-UHFFFAOYSA-N 0.000 description 4
- 201000001119 neuropathy Diseases 0.000 description 4
- 230000007823 neuropathy Effects 0.000 description 4
- 208000033808 peripheral neuropathy Diseases 0.000 description 4
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 238000006268 reductive amination reaction Methods 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- FWVSUNGWEKSBQM-UHFFFAOYSA-M tert-butyl 4-(3-methylimidazol-3-ium-1-yl)sulfonylpiperazine-1-carboxylate trifluoromethanesulfonate Chemical compound [O-]S(=O)(=O)C(F)(F)F.C[n+]1ccn(c1)S(=O)(=O)N1CCN(CC1)C(=O)OC(C)(C)C FWVSUNGWEKSBQM-UHFFFAOYSA-M 0.000 description 4
- 230000004572 zinc-binding Effects 0.000 description 4
- PNPCRKVUWYDDST-UHFFFAOYSA-N 3-chloroaniline Chemical compound NC1=CC=CC(Cl)=C1 PNPCRKVUWYDDST-UHFFFAOYSA-N 0.000 description 3
- YALRMXKAJOCAOY-UHFFFAOYSA-N 4-cyclobutyl-N-[[4-(hydrazinecarbonyl)phenyl]methyl]-N-phenylpiperazine-1-sulfonamide Chemical compound C1(CCC1)N1CCN(CC1)S(=O)(=O)N(C1=CC=CC=C1)CC1=CC=C(C=C1)C(=O)NN YALRMXKAJOCAOY-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- NEVUTCKQFWCPDN-UHFFFAOYSA-N N-(3-chloro-4-fluorophenyl)-4-cyclobutyl-N-[[4-(hydrazinecarbonyl)phenyl]methyl]piperazine-1-sulfonamide Chemical compound ClC=1C=C(C=CC=1F)N(S(=O)(=O)N1CCN(CC1)C1CCC1)CC1=CC=C(C=C1)C(=O)NN NEVUTCKQFWCPDN-UHFFFAOYSA-N 0.000 description 3
- SCYXOMNNCFFUKR-UHFFFAOYSA-N N-(3-chloro-4-fluorophenyl)-N-[[4-(hydrazinecarbonyl)phenyl]methyl]-4-methylpiperazine-1-sulfonamide Chemical compound ClC=1C=C(C=CC=1F)N(S(=O)(=O)N1CCN(CC1)C)CC1=CC=C(C=C1)C(=O)NN SCYXOMNNCFFUKR-UHFFFAOYSA-N 0.000 description 3
- WUTBVTKGRISCEY-UHFFFAOYSA-N N-(3-chloro-4-fluorophenyl)-N-[[4-(hydrazinecarbonyl)phenyl]methyl]-4-propan-2-ylpiperazine-1-sulfonamide Chemical compound ClC=1C=C(C=CC=1F)N(S(=O)(=O)N1CCN(CC1)C(C)C)CC1=CC=C(C=C1)C(=O)NN WUTBVTKGRISCEY-UHFFFAOYSA-N 0.000 description 3
- FIPORMSJLVMZAQ-UHFFFAOYSA-N N-(3-chloro-4-fluorophenyl)-N-[[5-(hydrazinecarbonyl)pyridin-2-yl]methyl]-1,1-dioxo-1,4-thiazinane-4-sulfonamide Chemical compound ClC=1C=C(C=CC=1F)N(S(=O)(=O)N1CCS(CC1)(=O)=O)CC1=NC=C(C=C1)C(=O)NN FIPORMSJLVMZAQ-UHFFFAOYSA-N 0.000 description 3
- CQQDVYKFQAQZNJ-UHFFFAOYSA-N N-(4-fluorophenyl)-N-[[4-(hydrazinecarbonyl)phenyl]methyl]morpholine-4-sulfonamide Chemical compound FC1=CC=C(C=C1)N(S(=O)(=O)N1CCOCC1)CC1=CC=C(C=C1)C(=O)NN CQQDVYKFQAQZNJ-UHFFFAOYSA-N 0.000 description 3
- FFIHKZARVLWSBF-UHFFFAOYSA-N N-[[4-(hydrazinecarbonyl)phenyl]methyl]-N-phenyl-4-propan-2-ylpiperazine-1-sulfonamide Chemical compound N(N)C(=O)C1=CC=C(CN(S(=O)(=O)N2CCN(CC2)C(C)C)C2=CC=CC=C2)C=C1 FFIHKZARVLWSBF-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 3
- 241000009298 Trigla lyra Species 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- OJBQAHZJVDWSFD-UHFFFAOYSA-N methyl 4-(bromomethyl)-3-fluorobenzoate Chemical compound COC(=O)C1=CC=C(CBr)C(F)=C1 OJBQAHZJVDWSFD-UHFFFAOYSA-N 0.000 description 3
- NLWBJPPMPLPZIE-UHFFFAOYSA-N methyl 4-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=C(CBr)C=C1 NLWBJPPMPLPZIE-UHFFFAOYSA-N 0.000 description 3
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical group NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 3
- 125000000565 sulfonamide group Chemical group 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- JEKVYWBEVCXPET-OKILXGFUSA-N tert-butyl (2R,6S)-2,6-dimethyl-4-(phenylsulfamoyl)piperazine-1-carboxylate Chemical compound C[C@@H]1N([C@@H](CN(C1)S(NC1=CC=CC=C1)(=O)=O)C)C(=O)OC(C)(C)C JEKVYWBEVCXPET-OKILXGFUSA-N 0.000 description 3
- OSJGNTQIRSHPHD-TXEJJXNPSA-N tert-butyl (2S,6R)-4-imidazol-1-ylsulfonyl-2,6-dimethylpiperazine-1-carboxylate Chemical compound N1(C=NC=C1)S(=O)(=O)N1C[C@@H](N([C@@H](C1)C)C(=O)OC(C)(C)C)C OSJGNTQIRSHPHD-TXEJJXNPSA-N 0.000 description 3
- MXZNXXGNDJWTPX-UHFFFAOYSA-N tert-butyl 4-[(3-fluorophenyl)sulfamoyl]piperazine-1-carboxylate Chemical compound FC=1C=C(C=CC=1)NS(=O)(=O)N1CCN(CC1)C(=O)OC(C)(C)C MXZNXXGNDJWTPX-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- NXNGMCKENGEZOG-OAHLLOKOSA-N (3R)-N-(3-chlorophenyl)-N-[[5-(hydrazinecarbonyl)pyridin-2-yl]methyl]-3-methyl-4-(oxetan-3-yl)piperazine-1-sulfonamide Chemical compound ClC=1C=C(C=CC=1)N(S(=O)(=O)N1C[C@H](N(CC1)C1COC1)C)CC1=NC=C(C=C1)C(=O)NN NXNGMCKENGEZOG-OAHLLOKOSA-N 0.000 description 2
- HBPXHBOXPPFFLL-HDICACEKSA-N (3R,5S)-4-ethyl-N-[[4-(hydrazinecarbonyl)phenyl]methyl]-3,5-dimethyl-N-phenylpiperazine-1-sulfonamide Chemical compound C(C)N1[C@H](CN(C[C@H]1C)S(=O)(=O)N(C1=CC=CC=C1)CC1=CC=C(C=C1)C(=O)NN)C HBPXHBOXPPFFLL-HDICACEKSA-N 0.000 description 2
- NXNGMCKENGEZOG-HNNXBMFYSA-N (3S)-N-(3-chlorophenyl)-N-[[5-(hydrazinecarbonyl)pyridin-2-yl]methyl]-3-methyl-4-(oxetan-3-yl)piperazine-1-sulfonamide Chemical compound ClC=1C=C(C=CC=1)N(S(=O)(=O)N1C[C@@H](N(CC1)C1COC1)C)CC1=NC=C(C=C1)C(=O)NN NXNGMCKENGEZOG-HNNXBMFYSA-N 0.000 description 2
- GTKRJDLEJFQFSO-CALCHBBNSA-N (3S,5R)-N-[[4-(hydrazinecarbonyl)phenyl]methyl]-3,4,5-trimethyl-N-phenylpiperazine-1-sulfonamide Chemical compound N(N)C(=O)C1=CC=C(CN(S(=O)(=O)N2C[C@@H](N([C@@H](C2)C)C)C)C2=CC=CC=C2)C=C1 GTKRJDLEJFQFSO-CALCHBBNSA-N 0.000 description 2
- IVSXPSZVWKOGIV-KDURUIRLSA-N (3S,5R)-N-[[4-(hydrazinecarbonyl)phenyl]methyl]-3,5-dimethyl-N-phenyl-4-propylpiperazine-1-sulfonamide Chemical compound N(N)C(=O)C1=CC=C(CN(S(=O)(=O)N2C[C@@H](N([C@@H](C2)C)CCC)C)C2=CC=CC=C2)C=C1 IVSXPSZVWKOGIV-KDURUIRLSA-N 0.000 description 2
- ZKYIQAJCERVIED-IYBDPMFKSA-N (3S,5R)-N-[[4-(hydrazinecarbonyl)phenyl]methyl]-3,5-dimethyl-N-phenylpiperazine-1-sulfonamide Chemical compound N(N)C(=O)C1=CC=C(CN(S(=O)(=O)N2C[C@@H](N[C@@H](C2)C)C)C2=CC=CC=C2)C=C1 ZKYIQAJCERVIED-IYBDPMFKSA-N 0.000 description 2
- SHWOZVSIKHTNSB-UHFFFAOYSA-N 1,1-dioxo-N-phenyl-1,4-thiazinane-4-sulfonamide Chemical compound C1(=CC=CC=C1)NS(=O)(=O)N1CCS(CC1)(=O)=O SHWOZVSIKHTNSB-UHFFFAOYSA-N 0.000 description 2
- VKCBXONEZGIOSP-UHFFFAOYSA-N 1-(4-methylphenyl)sulfonylazetidine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1CCC1 VKCBXONEZGIOSP-UHFFFAOYSA-N 0.000 description 2
- ZLKNPIVTWNMMMH-UHFFFAOYSA-N 1-imidazol-1-ylsulfonylimidazole Chemical compound C1=CN=CN1S(=O)(=O)N1C=CN=C1 ZLKNPIVTWNMMMH-UHFFFAOYSA-N 0.000 description 2
- JNJFONBBNLVENC-UHFFFAOYSA-N 1h-imidazole;trifluoromethanesulfonic acid Chemical compound C1=CNC=N1.OS(=O)(=O)C(F)(F)F JNJFONBBNLVENC-UHFFFAOYSA-N 0.000 description 2
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 2
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 2
- YSEMCVGMNUUNRK-UHFFFAOYSA-N 3-chloro-4-fluoroaniline Chemical compound NC1=CC=C(F)C(Cl)=C1 YSEMCVGMNUUNRK-UHFFFAOYSA-N 0.000 description 2
- CQXKCHQUVFFRFJ-UHFFFAOYSA-N 4-imidazol-1-ylsulfonyl-1,4-thiazinane 1,1-dioxide Chemical compound N1(C=NC=C1)S(=O)(=O)N1CCS(CC1)(=O)=O CQXKCHQUVFFRFJ-UHFFFAOYSA-N 0.000 description 2
- RNTXJGLFYBEDQD-UHFFFAOYSA-N 7-[[4-(hydrazinecarbonyl)phenyl]methyl-phenylsulfamoyl]-2,7-diazaspiro[3.5]nonane-2-carboxylic acid Chemical compound C1CN(CCC12CN(C2)C(=O)O)S(=O)(=O)N(CC3=CC=C(C=C3)C(=O)NN)C4=CC=CC=C4 RNTXJGLFYBEDQD-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000010061 Autosomal Dominant Polycystic Kidney Diseases 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- KBTBAVGKRMIBGG-UHFFFAOYSA-N N-(3-chloro-4-fluorophenyl)-1,1-dioxo-1,4-thiazinane-4-sulfonamide Chemical compound ClC=1C=C(C=CC=1F)NS(=O)(=O)N1CCS(CC1)(=O)=O KBTBAVGKRMIBGG-UHFFFAOYSA-N 0.000 description 2
- AQMBUIROCLSCGQ-UHFFFAOYSA-N N-(3-chloro-4-fluorophenyl)-N-[[5-(hydrazinecarbonyl)pyridin-2-yl]methyl]-4-(oxetan-3-yl)piperazine-1-sulfonamide Chemical compound ClC=1C=C(C=CC=1F)N(S(=O)(=O)N1CCN(CC1)C1COC1)CC1=NC=C(C=C1)C(=O)NN AQMBUIROCLSCGQ-UHFFFAOYSA-N 0.000 description 2
- MVKSCNPSFAUQTD-UHFFFAOYSA-N N-(3-chlorophenyl)-4-cyclobutyl-N-[[5-(hydrazinecarbonyl)pyridin-2-yl]methyl]piperazine-1-sulfonamide Chemical compound ClC=1C=C(C=CC=1)N(S(=O)(=O)N1CCN(CC1)C1CCC1)CC1=NC=C(C=C1)C(=O)NN MVKSCNPSFAUQTD-UHFFFAOYSA-N 0.000 description 2
- MQKGWPGZGHLHIS-UHFFFAOYSA-N N-[[4-(hydrazinecarbonyl)phenyl]methyl]-4-(oxetan-3-yl)-N-phenylpiperazine-1-sulfonamide Chemical compound N(N)C(=O)C1=CC=C(CN(S(=O)(=O)N2CCN(CC2)C2COC2)C2=CC=CC=C2)C=C1 MQKGWPGZGHLHIS-UHFFFAOYSA-N 0.000 description 2
- FOPLASVJJVASDO-UHFFFAOYSA-N N-[[5-(hydrazinecarbonyl)pyridin-2-yl]methyl]-1,1-dioxo-N-phenyl-1,4-thiazinane-4-sulfonamide Chemical compound N(N)C(=O)C=1C=CC(=NC=1)CN(S(=O)(=O)N1CCS(CC1)(=O)=O)C1=CC=CC=C1 FOPLASVJJVASDO-UHFFFAOYSA-N 0.000 description 2
- XDEVYCJFXACEHC-UHFFFAOYSA-N N-[[5-(hydrazinecarbonyl)pyridin-2-yl]methyl]-4-methyl-N-phenylpiperazine-1-sulfonamide Chemical compound N(N)C(=O)C=1C=CC(=NC=1)CN(S(=O)(=O)N1CCN(CC1)C)C1=CC=CC=C1 XDEVYCJFXACEHC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 208000019498 Skin and subcutaneous tissue disease Diseases 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001263 acyl chlorides Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- RWRIWBAIICGTTQ-UHFFFAOYSA-N anhydrous difluoromethane Natural products FCF RWRIWBAIICGTTQ-UHFFFAOYSA-N 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 208000022185 autosomal dominant polycystic kidney disease Diseases 0.000 description 2
- 150000003936 benzamides Chemical class 0.000 description 2
- JXHYCCGOZUGBFD-UHFFFAOYSA-N benzoic acid;hydrochloride Chemical compound Cl.OC(=O)C1=CC=CC=C1 JXHYCCGOZUGBFD-UHFFFAOYSA-N 0.000 description 2
- NHOWLEZFTHYCTP-UHFFFAOYSA-N benzylhydrazine Chemical compound NNCC1=CC=CC=C1 NHOWLEZFTHYCTP-UHFFFAOYSA-N 0.000 description 2
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 2
- YSHOWEKUVWPFNR-UHFFFAOYSA-N burgess reagent Chemical compound CC[N+](CC)(CC)S(=O)(=O)N=C([O-])OC YSHOWEKUVWPFNR-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 208000018631 connective tissue disease Diseases 0.000 description 2
- 238000003381 deacetylation reaction Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- XPSRLQQYJGNWTB-UHFFFAOYSA-N methyl 3-fluoro-4-[(N-piperazin-1-ylsulfonylanilino)methyl]benzoate hydrochloride Chemical compound Cl.COC(=O)c1ccc(CN(c2ccccc2)S(=O)(=O)N2CCNCC2)c(F)c1 XPSRLQQYJGNWTB-UHFFFAOYSA-N 0.000 description 2
- MOBCWOUSSISGBJ-UHFFFAOYSA-N methyl 4-(anilinomethyl)benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CNC1=CC=CC=C1 MOBCWOUSSISGBJ-UHFFFAOYSA-N 0.000 description 2
- WLQVHTIPLDJYAW-UHFFFAOYSA-N methyl 4-[[N-(methylsulfamoyl)anilino]methyl]benzoate Chemical compound CNS(=O)(=O)N(C1=CC=CC=C1)CC1=CC=C(C(=O)OC)C=C1 WLQVHTIPLDJYAW-UHFFFAOYSA-N 0.000 description 2
- PJDIEETUUQVXIN-UHFFFAOYSA-N methyl 4-[[N-[(2-methylpropan-2-yl)oxycarbonylsulfamoyl]anilino]methyl]benzoate Chemical compound C(C)(C)(C)OC(=O)NS(=O)(=O)N(C1=CC=CC=C1)CC1=CC=C(C(=O)OC)C=C1 PJDIEETUUQVXIN-UHFFFAOYSA-N 0.000 description 2
- MZDGXTXYHXDWIM-UHFFFAOYSA-N methyl benzoate;hydrochloride Chemical compound Cl.COC(=O)C1=CC=CC=C1 MZDGXTXYHXDWIM-UHFFFAOYSA-N 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- XKWXYSOAQOSDHI-UHFFFAOYSA-N methyl fluoromethanesulfonate Chemical compound COS(=O)(=O)CF XKWXYSOAQOSDHI-UHFFFAOYSA-N 0.000 description 2
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 2
- 208000005264 motor neuron disease Diseases 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 208000017445 musculoskeletal system disease Diseases 0.000 description 2
- 229960002715 nicotine Drugs 0.000 description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- RFIOZSIHFNEKFF-UHFFFAOYSA-N piperazine-1-carboxylic acid Chemical compound OC(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-N 0.000 description 2
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- 208000002320 spinal muscular atrophy Diseases 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 125000006253 t-butylcarbonyl group Chemical group [H]C([H])([H])C(C(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- YOLGYPLFPNHCTQ-GFCCVEGCSA-N tert-butyl (2R)-2-methyl-4-[(3-methyl-2H-imidazol-1-yl)sulfonyl]piperazine-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1[C@@H](CN(CC1)S(=O)(=O)N1CN(C=C1)C)C YOLGYPLFPNHCTQ-GFCCVEGCSA-N 0.000 description 2
- JUAMJJRBTUYYHL-CQSZACIVSA-N tert-butyl (2R)-2-methyl-4-[(3-methylphenyl)sulfamoyl]piperazine-1-carboxylate Chemical compound C[C@H]1N(CCN(C1)S(NC=1C=C(C=CC=1)C)(=O)=O)C(=O)OC(C)(C)C JUAMJJRBTUYYHL-CQSZACIVSA-N 0.000 description 2
- VTFFRINHSSWGGS-GFCCVEGCSA-N tert-butyl (2R)-4-[(3-chlorophenyl)sulfamoyl]-2-methylpiperazine-1-carboxylate Chemical compound ClC=1C=C(C=CC=1)NS(=O)(=O)N1C[C@H](N(CC1)C(=O)OC(C)(C)C)C VTFFRINHSSWGGS-GFCCVEGCSA-N 0.000 description 2
- DBKFFTQNQUMCCG-LJQANCHMSA-N tert-butyl (2R)-4-[(5-methoxycarbonylpyridin-2-yl)methyl-(3-methylphenyl)sulfamoyl]-2-methylpiperazine-1-carboxylate Chemical compound COC(=O)C=1C=CC(=NC=1)CN(S(=O)(=O)N1C[C@H](N(CC1)C(=O)OC(C)(C)C)C)C=1C=C(C=CC=1)C DBKFFTQNQUMCCG-LJQANCHMSA-N 0.000 description 2
- AZYSTQVBQRUVBG-LLVKDONJSA-N tert-butyl (2R)-4-imidazol-1-ylsulfonyl-2-methylpiperazine-1-carboxylate Chemical compound N1(C=NC=C1)S(=O)(=O)N1C[C@H](N(CC1)C(=O)OC(C)(C)C)C AZYSTQVBQRUVBG-LLVKDONJSA-N 0.000 description 2
- YKUQSOROGCXWAT-BETUJISGSA-N tert-butyl (2R,6S)-2,6-dimethyl-4-(pyridin-3-ylsulfamoyl)piperazine-1-carboxylate Chemical compound C[C@@H]1N([C@@H](CN(C1)S(NC=1C=NC=CC=1)(=O)=O)C)C(=O)OC(C)(C)C YKUQSOROGCXWAT-BETUJISGSA-N 0.000 description 2
- YOLGYPLFPNHCTQ-LBPRGKRZSA-N tert-butyl (2S)-2-methyl-4-[(3-methyl-2H-imidazol-1-yl)sulfonyl]piperazine-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1[C@H](CN(CC1)S(=O)(=O)N1CN(C=C1)C)C YOLGYPLFPNHCTQ-LBPRGKRZSA-N 0.000 description 2
- JUAMJJRBTUYYHL-AWEZNQCLSA-N tert-butyl (2S)-2-methyl-4-[(3-methylphenyl)sulfamoyl]piperazine-1-carboxylate Chemical compound C[C@@H]1N(CCN(C1)S(NC=1C=C(C=CC=1)C)(=O)=O)C(=O)OC(C)(C)C JUAMJJRBTUYYHL-AWEZNQCLSA-N 0.000 description 2
- VTFFRINHSSWGGS-LBPRGKRZSA-N tert-butyl (2S)-4-[(3-chlorophenyl)sulfamoyl]-2-methylpiperazine-1-carboxylate Chemical compound ClC=1C=C(C=CC=1)NS(=O)(=O)N1C[C@@H](N(CC1)C(=O)OC(C)(C)C)C VTFFRINHSSWGGS-LBPRGKRZSA-N 0.000 description 2
- DBKFFTQNQUMCCG-IBGZPJMESA-N tert-butyl (2S)-4-[(5-methoxycarbonylpyridin-2-yl)methyl-(3-methylphenyl)sulfamoyl]-2-methylpiperazine-1-carboxylate Chemical compound COC(=O)C=1C=CC(=NC=1)CN(S(=O)(=O)N1C[C@@H](N(CC1)C(=O)OC(C)(C)C)C)C=1C=C(C=CC=1)C DBKFFTQNQUMCCG-IBGZPJMESA-N 0.000 description 2
- AZYSTQVBQRUVBG-NSHDSACASA-N tert-butyl (2S)-4-imidazol-1-ylsulfonyl-2-methylpiperazine-1-carboxylate Chemical compound N1(C=NC=C1)S(=O)(=O)N1C[C@@H](N(CC1)C(=O)OC(C)(C)C)C AZYSTQVBQRUVBG-NSHDSACASA-N 0.000 description 2
- DATRVIMZZZVHMP-UHFFFAOYSA-N tert-butyl 2-methylpiperazine-1-carboxylate Chemical compound CC1CNCCN1C(=O)OC(C)(C)C DATRVIMZZZVHMP-UHFFFAOYSA-N 0.000 description 2
- FCMCINKRWALCCD-UHFFFAOYSA-N tert-butyl 4-(phenylsulfamoyl)piperazine-1-carboxylate Chemical compound C1(=CC=CC=C1)NS(=O)(=O)N1CCN(CC1)C(=O)OC(C)(C)C FCMCINKRWALCCD-UHFFFAOYSA-N 0.000 description 2
- NXIBBABATMYJPR-UHFFFAOYSA-N tert-butyl 4-(pyridin-3-ylsulfamoyl)piperazine-1-carboxylate Chemical compound N1=CC(=CC=C1)NS(=O)(=O)N1CCN(CC1)C(=O)OC(C)(C)C NXIBBABATMYJPR-UHFFFAOYSA-N 0.000 description 2
- MZCVXYJKPDYZIK-UHFFFAOYSA-N tert-butyl 4-[[2-fluoro-4-(hydrazinecarbonyl)phenyl]methyl-phenylsulfamoyl]piperazine-1-carboxylate Chemical compound FC1=C(CN(S(=O)(=O)N2CCN(CC2)C(=O)OC(C)(C)C)C2=CC=CC=C2)C=CC(=C1)C(=O)NN MZCVXYJKPDYZIK-UHFFFAOYSA-N 0.000 description 2
- IVCZXJKCRXSTIC-UHFFFAOYSA-N tert-butyl 4-imidazol-1-ylsulfonylpiperazine-1-carboxylate Chemical compound N1(C=NC=C1)S(=O)(=O)N1CCN(CC1)C(=O)OC(C)(C)C IVCZXJKCRXSTIC-UHFFFAOYSA-N 0.000 description 2
- BWHAQEBHTQZIRY-UHFFFAOYSA-N tert-butyl 7-imidazol-1-ylsulfonyl-2,7-diazaspiro[3.5]nonane-2-carboxylate Chemical compound N1(C=NC=C1)S(=O)(=O)N1CCC2(CN(C2)C(=O)OC(C)(C)C)CC1 BWHAQEBHTQZIRY-UHFFFAOYSA-N 0.000 description 2
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical compound CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- PPWCLGXCFRCCNO-CQSZACIVSA-N (3R)-N-(3-chlorophenyl)-N-[[5-(hydrazinecarbonyl)pyridin-2-yl]methyl]-3,4-dimethylpiperazine-1-sulfonamide Chemical compound ClC=1C=C(C=CC=1)N(S(=O)(=O)N1C[C@H](N(CC1)C)C)CC1=NC=C(C=C1)C(=O)NN PPWCLGXCFRCCNO-CQSZACIVSA-N 0.000 description 1
- SBOMWPMTDAODOQ-MRXNPFEDSA-N (3R)-N-[[5-(hydrazinecarbonyl)pyridin-2-yl]methyl]-3,4-dimethyl-N-(3-methylphenyl)piperazine-1-sulfonamide Chemical compound N(N)C(=O)C=1C=CC(=NC=1)CN(S(=O)(=O)N1C[C@H](N(CC1)C)C)C=1C=C(C=CC=1)C SBOMWPMTDAODOQ-MRXNPFEDSA-N 0.000 description 1
- WRWGULNQDAXMTR-QGZVFWFLSA-N (3R)-N-[[5-(hydrazinecarbonyl)pyridin-2-yl]methyl]-3-methyl-N-(3-methylphenyl)-4-(oxetan-3-yl)piperazine-1-sulfonamide Chemical compound N(N)C(=O)C=1C=CC(=NC=1)CN(S(=O)(=O)N1C[C@H](N(CC1)C1COC1)C)C=1C=C(C=CC=1)C WRWGULNQDAXMTR-QGZVFWFLSA-N 0.000 description 1
- PPWCLGXCFRCCNO-AWEZNQCLSA-N (3S)-N-(3-chlorophenyl)-N-[[5-(hydrazinecarbonyl)pyridin-2-yl]methyl]-3,4-dimethylpiperazine-1-sulfonamide Chemical compound ClC=1C=C(C=CC=1)N(S(=O)(=O)N1C[C@@H](N(CC1)C)C)CC1=NC=C(C=C1)C(=O)NN PPWCLGXCFRCCNO-AWEZNQCLSA-N 0.000 description 1
- SBOMWPMTDAODOQ-INIZCTEOSA-N (3S)-N-[[5-(hydrazinecarbonyl)pyridin-2-yl]methyl]-3,4-dimethyl-N-(3-methylphenyl)piperazine-1-sulfonamide Chemical compound N(N)C(=O)C=1C=CC(=NC=1)CN(S(=O)(=O)N1C[C@@H](N(CC1)C)C)C=1C=C(C=CC=1)C SBOMWPMTDAODOQ-INIZCTEOSA-N 0.000 description 1
- WRWGULNQDAXMTR-KRWDZBQOSA-N (3S)-N-[[5-(hydrazinecarbonyl)pyridin-2-yl]methyl]-3-methyl-N-(3-methylphenyl)-4-(oxetan-3-yl)piperazine-1-sulfonamide Chemical compound N(N)C(=O)C=1C=CC(=NC=1)CN(S(=O)(=O)N1C[C@@H](N(CC1)C1COC1)C)C=1C=C(C=CC=1)C WRWGULNQDAXMTR-KRWDZBQOSA-N 0.000 description 1
- NRNMQRZXSDAUNV-CALCHBBNSA-N (3S,5R)-4-acetyl-N-[[4-(hydrazinecarbonyl)phenyl]methyl]-3,5-dimethyl-N-phenylpiperazine-1-sulfonamide Chemical compound C(C)(=O)N1[C@H](CN(C[C@H]1C)S(=O)(=O)N(C1=CC=CC=C1)CC1=CC=C(C=C1)C(=O)NN)C NRNMQRZXSDAUNV-CALCHBBNSA-N 0.000 description 1
- NRKCUFCCWXJAAY-IYBDPMFKSA-N (3S,5R)-4-acetyl-N-[[4-(hydrazinecarbonyl)phenyl]methyl]-3,5-dimethyl-N-pyridin-3-ylpiperazine-1-sulfonamide Chemical compound C(C)(=O)N1[C@H](CN(C[C@H]1C)S(=O)(=O)N(C=1C=NC=CC=1)CC1=CC=C(C=C1)C(=O)NN)C NRKCUFCCWXJAAY-IYBDPMFKSA-N 0.000 description 1
- XANKMFKGBYYKEO-IYBDPMFKSA-N (3S,5R)-4-acetyl-N-[[5-(hydrazinecarbonyl)pyridin-2-yl]methyl]-3,5-dimethyl-N-phenylpiperazine-1-sulfonamide Chemical compound C(C)(=O)N1[C@H](CN(C[C@H]1C)S(=O)(=O)N(C1=CC=CC=C1)CC1=NC=C(C=C1)C(=O)NN)C XANKMFKGBYYKEO-IYBDPMFKSA-N 0.000 description 1
- PGIDISFWNCCCQU-CALCHBBNSA-N (3S,5R)-4-ethyl-N-[[5-(hydrazinecarbonyl)pyridin-2-yl]methyl]-3,5-dimethyl-N-phenylpiperazine-1-sulfonamide Chemical compound C(C)N1[C@H](CN(C[C@H]1C)S(=O)(=O)N(C1=CC=CC=C1)CC1=NC=C(C=C1)C(=O)NN)C PGIDISFWNCCCQU-CALCHBBNSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- SUBIUPDHPUVLDD-UHFFFAOYSA-N 1-cyclobutyl-4-phenylpiperazine Chemical compound C1CCC1N1CCN(C=2C=CC=CC=2)CC1 SUBIUPDHPUVLDD-UHFFFAOYSA-N 0.000 description 1
- OOUCDDZJJFIGRM-UHFFFAOYSA-N 1-imidazol-1-ylsulfonyl-3-methylimidazol-3-ium Chemical compound C1=[N+](C)C=CN1S(=O)(=O)N1C=NC=C1 OOUCDDZJJFIGRM-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- WVEBNSTWFGYBHI-UHFFFAOYSA-N 2,7-diazaspiro[3.5]nonane-2-carboxylic acid Chemical compound C1N(C(=O)O)CC21CCNCC2 WVEBNSTWFGYBHI-UHFFFAOYSA-N 0.000 description 1
- AUMAXZCGVGVTFQ-UHFFFAOYSA-M 2-(bromomethyl)-3-methylbenzoate Chemical compound CC1=CC=CC(C([O-])=O)=C1CBr AUMAXZCGVGVTFQ-UHFFFAOYSA-M 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- HNZOCVKGAUHUGX-UHFFFAOYSA-N 2-methyl-N-phenylpiperazine-1-sulfonamide Chemical compound CC1N(CCNC1)S(=O)(=O)NC1=CC=CC=C1 HNZOCVKGAUHUGX-UHFFFAOYSA-N 0.000 description 1
- BSMNBEHEFWDHJD-UHFFFAOYSA-N 2-methylpropan-1-amine;hydrochloride Chemical compound [Cl-].CC(C)C[NH3+] BSMNBEHEFWDHJD-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- OPIVCPUTMHQKPH-UHFFFAOYSA-N 2-phenylpiperazine-1-sulfonamide Chemical compound NS(=O)(=O)N1CCNCC1C1=CC=CC=C1 OPIVCPUTMHQKPH-UHFFFAOYSA-N 0.000 description 1
- WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 1
- QZVQQUVWFIZUBQ-UHFFFAOYSA-N 3-fluoroaniline Chemical compound NC1=CC=CC(F)=C1 QZVQQUVWFIZUBQ-UHFFFAOYSA-N 0.000 description 1
- SQIQQEFNYTXCJY-UHFFFAOYSA-N 4-(2-hydroxyethyl)piperazine-1-carboxylic acid Chemical compound OCCN1CCN(C(O)=O)CC1 SQIQQEFNYTXCJY-UHFFFAOYSA-N 0.000 description 1
- VYZDEUGUZRPXQK-UHFFFAOYSA-N 4-(oxetan-3-yl)-N-phenyl-N-[[5-[[(2,2,2-trifluoroacetyl)amino]carbamoyl]pyridin-2-yl]methyl]piperazine-1-sulfonamide Chemical compound O1CC(C1)N1CCN(CC1)S(=O)(=O)N(CC1=NC=C(C=C1)C(=O)NNC(C(F)(F)F)=O)C1=CC=CC=C1 VYZDEUGUZRPXQK-UHFFFAOYSA-N 0.000 description 1
- QRQWYPKABLVERW-UHFFFAOYSA-N 4-[(2-fluoro-4-methoxycarbonylphenyl)methyl-(3-fluorophenyl)sulfamoyl]piperazine-1-carboxylic acid Chemical compound FC1=C(CN(S(=O)(=O)N2CCN(CC2)C(=O)O)C2=CC(=CC=C2)F)C=CC(=C1)C(=O)OC QRQWYPKABLVERW-UHFFFAOYSA-N 0.000 description 1
- HSTLIUBJILKINY-UHFFFAOYSA-N 4-[[2-fluoro-4-(hydrazinecarbonyl)phenyl]methyl-(3-fluorophenyl)sulfamoyl]piperazine-1-carboxylic acid Chemical compound FC1=C(CN(S(=O)(=O)N2CCN(CC2)C(=O)O)C2=CC(=CC=C2)F)C=CC(=C1)C(=O)NN HSTLIUBJILKINY-UHFFFAOYSA-N 0.000 description 1
- PQYIMZHGCKWBAU-UHFFFAOYSA-N 4-imidazol-1-ylsulfonylthiomorpholine Chemical compound C1=CN=CN1S(=O)(=O)N1CCSCC1 PQYIMZHGCKWBAU-UHFFFAOYSA-N 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 244000140786 Brassica hirta Species 0.000 description 1
- 235000011371 Brassica hirta Nutrition 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- KOQHHMKXSKDMCO-UHFFFAOYSA-N CC1N(CCNC1)S(=O)(=O)NC=1C=NC=CC1 Chemical compound CC1N(CCNC1)S(=O)(=O)NC=1C=NC=CC1 KOQHHMKXSKDMCO-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000015879 Cerebellar disease Diseases 0.000 description 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 102100039869 Histone H2B type F-S Human genes 0.000 description 1
- 102100039996 Histone deacetylase 1 Human genes 0.000 description 1
- 102100021454 Histone deacetylase 4 Human genes 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 description 1
- 101000899259 Homo sapiens Histone deacetylase 4 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010022031 Inherited neuropathies Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- IIBMRSXNBKZXTI-UHFFFAOYSA-N N-(3-chloro-4-fluorophenyl)-4-cyclobutyl-N-[[5-(hydrazinecarbonyl)pyridin-2-yl]methyl]piperazine-1-sulfonamide Chemical compound ClC=1C=C(C=CC=1F)N(S(=O)(=O)N1CCN(CC1)C1CCC1)CC1=NC=C(C=C1)C(=O)NN IIBMRSXNBKZXTI-UHFFFAOYSA-N 0.000 description 1
- NTOWMRFNKIELOF-UHFFFAOYSA-N N-(3-chloro-4-fluorophenyl)-N-[[4-(hydrazinecarbonyl)phenyl]methyl]-4-(oxetan-3-yl)piperazine-1-sulfonamide Chemical compound ClC=1C=C(C=CC=1F)N(S(=O)(=O)N1CCN(CC1)C1COC1)CC1=CC=C(C=C1)C(=O)NN NTOWMRFNKIELOF-UHFFFAOYSA-N 0.000 description 1
- BEESKMIESFQATF-UHFFFAOYSA-N N-(3-chloro-4-fluorophenyl)-N-[[5-(hydrazinecarbonyl)pyridin-2-yl]methyl]-4-propan-2-ylpiperazine-1-sulfonamide Chemical compound ClC=1C=C(C=CC=1F)N(S(=O)(=O)N1CCN(CC1)C(C)C)CC1=NC=C(C=C1)C(=O)NN BEESKMIESFQATF-UHFFFAOYSA-N 0.000 description 1
- ITNRCRBPICCVRF-UHFFFAOYSA-N N-(3-chlorophenyl)-N-[[5-(hydrazinecarbonyl)pyridin-2-yl]methyl]-4-(oxetan-3-yl)piperazine-1-sulfonamide Chemical compound ClC=1C=C(C=CC=1)N(S(=O)(=O)N1CCN(CC1)C1COC1)CC1=NC=C(C=C1)C(=O)NN ITNRCRBPICCVRF-UHFFFAOYSA-N 0.000 description 1
- BJBOWDALRUFJLC-UHFFFAOYSA-N N-[[2-fluoro-4-(hydrazinecarbonyl)phenyl]methyl]-4-(oxetan-3-yl)-N-phenylpiperazine-1-sulfonamide Chemical compound FC1=C(CN(S(=O)(=O)N2CCN(CC2)C2COC2)C2=CC=CC=C2)C=CC(=C1)C(=O)NN BJBOWDALRUFJLC-UHFFFAOYSA-N 0.000 description 1
- XOKMXDBQCPAIAD-UHFFFAOYSA-N N-[[2-fluoro-4-[[(2,2,2-trifluoroacetyl)amino]carbamoyl]phenyl]methyl]-4-(oxetan-3-yl)-N-phenylpiperazine-1-sulfonamide Chemical compound FC1=C(CN(S(=O)(=O)N2CCN(CC2)C2COC2)C2=CC=CC=C2)C=CC(=C1)C(=O)NNC(C(F)(F)F)=O XOKMXDBQCPAIAD-UHFFFAOYSA-N 0.000 description 1
- AINBCYKSGSHONS-UHFFFAOYSA-N N-[[4-[[(2,2-difluoroacetyl)amino]carbamoyl]-2-fluorophenyl]methyl]-4-(oxetan-3-yl)-N-phenylpiperazine-1-sulfonamide Chemical compound FC(C(=O)NNC(=O)C1=CC(=C(CN(S(=O)(=O)N2CCN(CC2)C2COC2)C2=CC=CC=C2)C=C1)F)F AINBCYKSGSHONS-UHFFFAOYSA-N 0.000 description 1
- TXDXMESLKFPIPG-UHFFFAOYSA-N N-[[5-(hydrazinecarbonyl)pyridin-2-yl]methyl]-4-(oxetan-3-yl)-N-phenylpiperazine-1-sulfonamide Chemical compound N(N)C(=O)C=1C=CC(=NC=1)CN(S(=O)(=O)N1CCN(CC1)C1COC1)C1=CC=CC=C1 TXDXMESLKFPIPG-UHFFFAOYSA-N 0.000 description 1
- KICXPSMHEVWYGF-UHFFFAOYSA-N N-[[5-[[(2,2-difluoroacetyl)amino]carbamoyl]pyridin-2-yl]methyl]-1,1-dioxo-N-phenyl-1,4-thiazinane-4-sulfonamide Chemical compound FC(C(=O)NNC(=O)C=1C=CC(=NC=1)CN(S(=O)(=O)N1CCS(CC1)(=O)=O)C1=CC=CC=C1)F KICXPSMHEVWYGF-UHFFFAOYSA-N 0.000 description 1
- FUMHCSLIXZRMJU-UHFFFAOYSA-N N-phenylthiomorpholine-4-sulfonamide Chemical compound C1(=CC=CC=C1)NS(=O)(=O)N1CCSCC1 FUMHCSLIXZRMJU-UHFFFAOYSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- SZTLIGHKSIXTGE-UHFFFAOYSA-N O1CC(C1)N1CCN(CC1)C1=CC=CC=C1 Chemical compound O1CC(C1)N1CCN(CC1)C1=CC=CC=C1 SZTLIGHKSIXTGE-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102100039388 Polyamine deacetylase HDAC10 Human genes 0.000 description 1
- 101710107444 Polyamine deacetylase HDAC10 Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- 108050002485 Sirtuin Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108010005705 Ubiquitinated Proteins Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 125000006242 amine protecting group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002332 glycine derivatives Chemical class 0.000 description 1
- QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006195 histone acetylation Effects 0.000 description 1
- 230000006197 histone deacetylation Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- IUMCYXJTHIYBEU-UHFFFAOYSA-N methyl 3-fluoro-4-[(N-piperazin-1-ylsulfonylanilino)methyl]benzoate Chemical compound FC=1C=C(C(=O)OC)C=CC=1CN(S(=O)(=O)N1CCNCC1)C1=CC=CC=C1 IUMCYXJTHIYBEU-UHFFFAOYSA-N 0.000 description 1
- BYTIPABZLJGXMC-UHFFFAOYSA-N methyl 4-[(4-fluoro-N-morpholin-4-ylsulfonylanilino)methyl]benzoate Chemical compound FC1=CC=C(C=C1)N(S(=O)(=O)N1CCOCC1)CC1=CC=C(C(=O)OC)C=C1 BYTIPABZLJGXMC-UHFFFAOYSA-N 0.000 description 1
- KYHIHYXMHJHYAE-CALCHBBNSA-N methyl 4-[(N-[(3R,5S)-3,5-dimethylpiperazin-1-yl]sulfonylanilino)methyl]benzoate Chemical compound COC(=O)C1=CC=C(CN(C2=CC=CC=C2)S(=O)(=O)N2C[C@H](C)N[C@H](C)C2)C=C1 KYHIHYXMHJHYAE-CALCHBBNSA-N 0.000 description 1
- XWMIOLWCYXVLKZ-UHFFFAOYSA-N methyl 4-[(N-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]sulfamoyl]anilino)methyl]benzoate Chemical compound C(C)(C)(C)OC(=O)N(S(=O)(=O)N(C1=CC=CC=C1)CC1=CC=C(C(=O)OC)C=C1)C XWMIOLWCYXVLKZ-UHFFFAOYSA-N 0.000 description 1
- RRIZRBLHDZPNJB-UHFFFAOYSA-N methyl 4-[(N-[methyl-[2-(4-methylpiperazin-1-yl)ethyl]sulfamoyl]anilino)methyl]benzoate Chemical compound CN(S(=O)(=O)N(C1=CC=CC=C1)CC1=CC=C(C(=O)OC)C=C1)CCN1CCN(CC1)C RRIZRBLHDZPNJB-UHFFFAOYSA-N 0.000 description 1
- JAIMFHLKMNXHOL-UHFFFAOYSA-N methyl 4-[(N-[methyl-[2-(4-methylsulfonylpiperazin-1-yl)ethyl]sulfamoyl]anilino)methyl]benzoate Chemical compound CN(S(=O)(=O)N(C1=CC=CC=C1)CC1=CC=C(C(=O)OC)C=C1)CCN1CCN(CC1)S(=O)(=O)C JAIMFHLKMNXHOL-UHFFFAOYSA-N 0.000 description 1
- 229960001238 methylnicotinate Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- WZWQJRQCWCFUTM-UHFFFAOYSA-N morpholine-4-sulfonamide Chemical compound NS(=O)(=O)N1CCOCC1 WZWQJRQCWCFUTM-UHFFFAOYSA-N 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- HFKOSUWCYKFGFN-UHFFFAOYSA-N n-phenylpiperazine-1-sulfonamide Chemical compound C1CNCCN1S(=O)(=O)NC1=CC=CC=C1 HFKOSUWCYKFGFN-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012740 non-selective inhibitor Substances 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- REIDAMBAPLIATC-UHFFFAOYSA-N p-terephthalic acid monomethyl ester Natural products COC(=O)C1=CC=C(C(O)=O)C=C1 REIDAMBAPLIATC-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- XFIUZEAHIJGTTB-UHFFFAOYSA-N pyridine-4-sulfonamide Chemical compound NS(=O)(=O)C1=CC=NC=C1 XFIUZEAHIJGTTB-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960003452 romidepsin Drugs 0.000 description 1
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 1
- 108010091666 romidepsin Proteins 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- DNYNOAZZKBMKEY-QGZVFWFLSA-N tert-butyl (2R)-4-[(3-chlorophenyl)-[(5-methoxycarbonylpyridin-2-yl)methyl]sulfamoyl]-2-methylpiperazine-1-carboxylate Chemical compound ClC=1C=C(C=CC=1)N(S(=O)(=O)N1C[C@H](N(CC1)C(=O)OC(C)(C)C)C)CC1=NC=C(C=C1)C(=O)OC DNYNOAZZKBMKEY-QGZVFWFLSA-N 0.000 description 1
- CBOTWIPHDYJGCT-KDURUIRLSA-N tert-butyl (2R,6S)-4-[(4-methoxycarbonylphenyl)methyl-pyridin-3-ylsulfamoyl]-2,6-dimethylpiperazine-1-carboxylate Chemical compound COC(=O)C1=CC=C(CN(S(=O)(=O)N2C[C@@H](N([C@@H](C2)C)C(=O)OC(C)(C)C)C)C=2C=NC=CC=2)C=C1 CBOTWIPHDYJGCT-KDURUIRLSA-N 0.000 description 1
- DNYNOAZZKBMKEY-KRWDZBQOSA-N tert-butyl (2S)-4-[(3-chlorophenyl)-[(5-methoxycarbonylpyridin-2-yl)methyl]sulfamoyl]-2-methylpiperazine-1-carboxylate Chemical compound ClC=1C=C(C=CC=1)N(S(=O)(=O)N1C[C@@H](N(CC1)C(=O)OC(C)(C)C)C)CC1=NC=C(C=C1)C(=O)OC DNYNOAZZKBMKEY-KRWDZBQOSA-N 0.000 description 1
- ZBCMUHWEHQJMNT-UHFFFAOYSA-N tert-butyl 2-methylnonanoate Chemical compound CCCCCCCC(C)C(=O)OC(C)(C)C ZBCMUHWEHQJMNT-UHFFFAOYSA-N 0.000 description 1
- FPQSSQQQKLJLPA-UHFFFAOYSA-N tert-butyl 3-(2-hydroxyethyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNC(CCO)C1 FPQSSQQQKLJLPA-UHFFFAOYSA-N 0.000 description 1
- XSBOTWUEDYMRKM-UHFFFAOYSA-N tert-butyl 4-(2-methylsulfonyloxyethyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(CCOS(C)(=O)=O)CC1 XSBOTWUEDYMRKM-UHFFFAOYSA-N 0.000 description 1
- XJHPHMOTAYJRBG-UHFFFAOYSA-N tert-butyl 4-[(3-chlorophenyl)-[(5-methoxycarbonylpyridin-2-yl)methyl]sulfamoyl]piperazine-1-carboxylate Chemical compound ClC=1C=C(C=CC=1)N(S(=O)(=O)N1CCN(CC1)C(=O)OC(C)(C)C)CC1=NC=C(C=C1)C(=O)OC XJHPHMOTAYJRBG-UHFFFAOYSA-N 0.000 description 1
- SBPUPXVDVXRSRS-UHFFFAOYSA-N tert-butyl 4-[(3-chlorophenyl)sulfamoyl]piperazine-1-carboxylate Chemical compound ClC=1C=C(C=CC=1)NS(=O)(=O)N1CCN(CC1)C(=O)OC(C)(C)C SBPUPXVDVXRSRS-UHFFFAOYSA-N 0.000 description 1
- CDIHFTFPAMXLPR-UHFFFAOYSA-N tert-butyl 7-(phenylsulfamoyl)-2,7-diazaspiro[3.5]nonane-2-carboxylate Chemical compound C1(=CC=CC=C1)NS(=O)(=O)N1CCC2(CN(C2)C(=O)OC(C)(C)C)CC1 CDIHFTFPAMXLPR-UHFFFAOYSA-N 0.000 description 1
- DHIMTNJVFMCKTP-UHFFFAOYSA-N tert-butyl 7-[(4-methoxycarbonylphenyl)methyl-phenylsulfamoyl]-2,7-diazaspiro[3.5]nonane-2-carboxylate Chemical compound COC(=O)C1=CC=C(CN(S(=O)(=O)N2CCC3(CN(C3)C(=O)OC(C)(C)C)CC2)C2=CC=CC=C2)C=C1 DHIMTNJVFMCKTP-UHFFFAOYSA-N 0.000 description 1
- VBYPJHLRWKGNAI-UHFFFAOYSA-N tert-butyl aziridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC1 VBYPJHLRWKGNAI-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2015-0106177 | 2015-07-27 | ||
| KR20150106177 | 2015-07-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201712007A TW201712007A (zh) | 2017-04-01 |
| TWI694074B true TWI694074B (zh) | 2020-05-21 |
Family
ID=57885712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW105123853A TWI694074B (zh) | 2015-07-27 | 2016-07-27 | 作為組蛋白去乙醯酶６抑制劑之１,３,４-㗁二唑磺醯胺衍生物及含彼之醫藥組合物 |
Country Status (21)
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016179550A1 (en) | 2015-05-07 | 2016-11-10 | Chdi Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
| EP3291810B1 (en) | 2015-05-07 | 2022-08-10 | CHDI Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
| RU2700696C2 (ru) | 2015-07-27 | 2019-09-19 | Чонг Кун Данг Фармасьютикал Корп. | 1,3,4,-оксадизоламидное производное соединение в качестве ингибитора гистондеацетилазы 6 и содержащая его фармацевтическая композиция |
| NZ736432A (en) | 2015-07-27 | 2019-01-25 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| WO2017018803A1 (en) | 2015-07-27 | 2017-02-02 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| HUE057544T2 (hu) | 2015-08-04 | 2022-05-28 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazol-származék vegyületek mint hiszton deacetiláz 6 inhibitorok, és ezeket tartalmazó gyógyszerkészítmények |
| RU2695133C1 (ru) | 2015-10-12 | 2019-07-22 | Чонг Кун Данг Фармасьютикал Корп. | Производные оксадиазоламина в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция |
| US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
| US10435399B2 (en) | 2017-07-31 | 2019-10-08 | Takeda Pharmaceutical Company Limited | HDAC6 inhibitory heterocyclic compound |
| KR102059027B1 (ko) * | 2018-01-12 | 2019-12-24 | 주식회사 비엔에이치리서치 | Hdac6 억제제를 유효성분으로 포함하는 가려움증 예방 또는 치료용 약제학적 조성물 |
| KR102316234B1 (ko) * | 2018-07-26 | 2021-10-22 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| WO2020158762A1 (ja) | 2019-01-30 | 2020-08-06 | 武田薬品工業株式会社 | 複素環化合物 |
| ES2984772T3 (es) * | 2019-04-17 | 2024-10-31 | Quimatryx S L | Derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasas |
| EP3976602A4 (en) | 2019-05-31 | 2023-05-31 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-OXADIAZOLE HOMOPHTHALIMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE-6 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF |
| JP2022538284A (ja) | 2019-06-27 | 2022-09-01 | ザ ジョージ ワシントン ユニバーシティ， ア コングレッショナリー チャータード ノット－フォー－プロフィット コーポレイション | Ｈｄａｃ６活性化マクロファージ、その組成物および使用 |
| TWI882012B (zh) | 2019-09-27 | 2025-05-01 | 日商武田藥品工業股份有限公司 | 雜環化合物 |
| CA3165424A1 (en) | 2019-12-20 | 2021-06-24 | Tenaya Therapeutics, Inc. | Fluoroalkyl-oxadiazoles and uses thereof |
| KR102537616B1 (ko) * | 2020-02-25 | 2023-05-26 | 주식회사 종근당 | 히스톤 탈아세틸화 효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| PH12023550101A1 (en) * | 2020-07-14 | 2024-06-24 | Chong Kun Dang Pharmaceutical Corp | Novel compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same |
| JP2023537052A (ja) | 2020-08-07 | 2023-08-30 | イタルファルマコ ソシエタ ペル アチオニ | 新規オキサジアゾール系の選択的ｈｄａｃ６阻害剤 |
| TWI844004B (zh) * | 2021-04-08 | 2024-06-01 | 韓商鐘根堂股份有限公司 | 二唑硫羰基化合物及包含該等化合物之醫藥組合物 |
| KR20240013098A (ko) | 2021-04-23 | 2024-01-30 | 테나야 테라퓨틱스, 인코포레이티드 | 확장성 심근병증의 치료에 사용하기 위한 hdac6 억제제 |
| EP4333841A1 (en) | 2021-05-04 | 2024-03-13 | Tenaya Therapeutics, Inc. | 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef |
| TW202412772A (zh) | 2022-07-19 | 2024-04-01 | 義大利商義大利藥品股份有限公司 | 作為選擇性組蛋白去乙醯酶６抑制劑之１，３，４－㗁二唑衍生物 |
| WO2024033293A1 (en) | 2022-08-08 | 2024-02-15 | Italfarmaco S.P.A. | Difluoro- and trifluoro-acetyl hydrazides as selective hdac6 inhibitors |
| KR20240035172A (ko) * | 2022-09-08 | 2024-03-15 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이의 용도 |
| JP2025533206A (ja) * | 2022-10-14 | 2025-10-03 | チョン クン ダン ファーマシューティカル コーポレイション | ヒストンデアセチラーゼ６阻害剤としてのスルホキシイミン化合物及びそれを含む医薬組成物 |
| WO2025215092A1 (en) | 2024-04-10 | 2025-10-16 | Institut National de la Santé et de la Recherche Médicale | Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0276432A3 (de) | 1986-12-12 | 1988-10-26 | Ciba-Geigy Ag | Schädlingsbekämpfungsmittel |
| KR100265385B1 (ko) | 1998-02-27 | 2000-11-01 | 윤여표 | 순환기 질환의 예방 및 치료 효능을 갖는 홍경천 추출물 |
| US7868204B2 (en) | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| WO2003028729A2 (en) | 2001-10-03 | 2003-04-10 | Pharmacia Corporation | Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade |
| DK1465861T3 (da) | 2001-12-20 | 2009-08-31 | Bristol Myers Squibb Co | Alpha-(N-sulfonamid)acetamidderivater som beta-amyloidhæmmere |
| AU2006270322A1 (en) | 2005-07-14 | 2007-01-25 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| AU2006278397B2 (en) | 2005-08-04 | 2013-01-17 | Sirtris Pharmaceuticals, Inc. | Oxazolopyridine derivatives as sirtuin modulators |
| WO2007032445A1 (ja) | 2005-09-16 | 2007-03-22 | Kyowa Hakko Kogyo Co., Ltd. | タンパク質キナーゼ阻害剤 |
| US8088791B2 (en) | 2006-03-23 | 2012-01-03 | Biots Scientific Management Pty Ltd | Antibacterial agents |
| WO2007143822A1 (en) * | 2006-06-14 | 2007-12-21 | Methylgene Inc. | Sulfamide and sulfamate derivatives as histone deacetylase inhibitors |
| EP1878730A1 (en) | 2006-07-12 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same |
| EP2099489B1 (en) | 2006-12-11 | 2014-05-21 | Genentech, Inc. | Compositions and methods for treating a neoplasm |
| WO2009010479A2 (en) | 2007-07-13 | 2009-01-22 | Euroscreen S.A. | Heterocyclic methylene piperidine derivatives and their use |
| KR100903743B1 (ko) | 2007-08-28 | 2009-06-19 | 전병태 | 소화기계 질환개선 및 예방용 식품 조성물 |
| RU2010122324A (ru) | 2007-11-02 | 2011-12-10 | Момента Фармасьютикалз, Инк. (Us) | Полисахаридные композиции, не обладающие антикоагулянтными свойствами |
| BRPI0817897A2 (pt) | 2007-11-02 | 2019-09-24 | Methylgene Inc | composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac |
| AU2009274549B2 (en) | 2008-07-23 | 2014-05-01 | Dana-Farber Cancer Institute, Inc. | Deacetylase inhibitors and uses thereof |
| WO2010123933A1 (en) | 2009-04-20 | 2010-10-28 | Institute For Oneworld Health | Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives |
| WO2010126002A1 (ja) | 2009-04-28 | 2010-11-04 | 塩野義製薬株式会社 | ヘテロ環スルホンアミド化合物を含有する医薬 |
| JP2011008205A (ja) | 2009-05-27 | 2011-01-13 | Fujifilm Corp | 二軸性光学異方性膜を作製するための組成物 |
| CA2768466C (en) | 2009-07-22 | 2018-08-14 | The Board Of Trustees Of The University Of Illinois | Hdac inhibitors and therapeutic methods using the same |
| WO2011088181A1 (en) | 2010-01-13 | 2011-07-21 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| EP2523664A4 (en) | 2010-01-13 | 2013-06-26 | Tempero Pharmaceuticals Inc | COMPOUNDS AND METHODS |
| PL2526093T3 (pl) | 2010-01-22 | 2017-02-28 | Acetylon Pharmaceuticals, Inc. | Odwrócone związki amidowe jako inhibitory deacetylazy białkowej oraz sposoby ich stosowania |
| KR20130010895A (ko) | 2010-02-25 | 2013-01-29 | 피라말 엔터프라이지즈 리미티드 | 옥사디아졸 화합물, 그의 제조방법 및 용도 |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| AU2011253025A1 (en) | 2010-05-12 | 2012-11-29 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US8697739B2 (en) | 2010-07-29 | 2014-04-15 | Novartis Ag | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof |
| EP3216798A3 (en) | 2010-12-09 | 2017-10-25 | Wockhardt Limited | Ketolide compounds |
| KR101262870B1 (ko) | 2011-01-28 | 2013-05-09 | 환인제약 주식회사 | 호장근 추출물을 함유하는 호흡기 질환의 예방 또는 치료용 조성물 |
| EA201490228A1 (ru) | 2011-07-08 | 2014-08-29 | Новартис Аг | Новые производные трифторметилоксадиазола и их применение для лечения заболевания |
| US9512083B2 (en) | 2011-07-20 | 2016-12-06 | The General Hospital Corporation | Histone deacetylase 6 selective inhibitors for the treatment of bone disease |
| WO2013041407A1 (en) | 2011-09-19 | 2013-03-28 | Cellzome Ag | Hydroxamic acids as hdac6 inhibitors |
| AU2012319188B2 (en) | 2011-10-03 | 2016-11-24 | Sloan-Kettering Institute For Cancer Research | Novel molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1 |
| WO2013066839A2 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066838A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066835A2 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066833A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods to inhibit histone deacetylase (hdac) enzymes |
| KR20140097459A (ko) | 2011-11-28 | 2014-08-06 | 노파르티스 아게 | 신규 트리플루오로메틸-옥사디아졸 유도체 및 질환의 치료에서의 그의 용도 |
| JP6272773B2 (ja) | 2011-11-29 | 2018-01-31 | ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． | Ｈｄａｃ６阻害剤・抗腫瘍剤用複素環アミド化合物 |
| JP6233812B2 (ja) | 2012-03-07 | 2017-11-22 | エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド | 選択的ヒストンデアセチラーゼ６阻害剤 |
| SMT201800421T1 (it) | 2013-09-06 | 2018-09-13 | Aurigene Discovery Tech Ltd | Derivati di 1,3,4-ossadiazolo e 1,3,4-tiadiazolo come immunomodulatori |
| PT3080125T (pt) | 2013-12-12 | 2018-12-14 | Chong Kun Dang Pharmaceutical Corp | Novos derivados de azaindole como inibidores seletivos da histona-desacetilase (hdac) e composições farmacêuticas que compreendem os mesmos |
| CN104744446B (zh) | 2013-12-30 | 2019-06-25 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| BR112017010402B1 (pt) | 2014-11-24 | 2023-12-12 | Medifron Dbt Inc | Carboxamida substituída à base de tiazol e oxazol e derivados de ureia como ligantes de receptor vanilóide ii |
| CN106349451B (zh) | 2015-07-14 | 2020-11-13 | 罗门哈斯公司 | 用于制备疏水改性环氧烷氨基甲酸酯聚合物的方法 |
| NZ736432A (en) | 2015-07-27 | 2019-01-25 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| WO2017018803A1 (en) | 2015-07-27 | 2017-02-02 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| RU2700696C2 (ru) * | 2015-07-27 | 2019-09-19 | Чонг Кун Данг Фармасьютикал Корп. | 1,3,4,-оксадизоламидное производное соединение в качестве ингибитора гистондеацетилазы 6 и содержащая его фармацевтическая композиция |
| HUE057544T2 (hu) | 2015-08-04 | 2022-05-28 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazol-származék vegyületek mint hiszton deacetiláz 6 inhibitorok, és ezeket tartalmazó gyógyszerkészítmények |
| RU2695133C1 (ru) | 2015-10-12 | 2019-07-22 | Чонг Кун Данг Фармасьютикал Корп. | Производные оксадиазоламина в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция |
-
2016
- 2016-07-27 NZ NZ736432A patent/NZ736432A/en unknown
- 2016-07-27 TW TW105123853A patent/TWI694074B/zh active
- 2016-07-27 MX MX2017017090A patent/MX376585B/es active IP Right Grant
- 2016-07-27 MY MYPI2017703935A patent/MY194018A/en unknown
- 2016-07-27 PL PL16830838T patent/PL3328844T3/pl unknown
- 2016-07-27 HU HUE16830838A patent/HUE048534T2/hu unknown
- 2016-07-27 AU AU2016299486A patent/AU2016299486B2/en active Active
- 2016-07-27 KR KR1020160095326A patent/KR101799005B1/ko active Active
- 2016-07-27 CN CN201680025249.5A patent/CN107980040B/zh active Active
- 2016-07-27 ES ES16830838T patent/ES2774510T3/es active Active
- 2016-07-27 RU RU2018106904A patent/RU2695227C9/ru active
- 2016-07-27 DK DK16830838.5T patent/DK3328844T3/da active
- 2016-07-27 WO PCT/KR2016/008218 patent/WO2017018805A1/en not_active Ceased
- 2016-07-27 PT PT168308385T patent/PT3328844T/pt unknown
- 2016-07-27 CA CA2987570A patent/CA2987570C/en active Active
- 2016-07-27 JP JP2018504096A patent/JP6538266B2/ja active Active
- 2016-07-27 HR HRP20200280TT patent/HRP20200280T1/hr unknown
- 2016-07-27 EP EP16830838.5A patent/EP3328844B1/en active Active
- 2016-07-27 US US15/747,850 patent/US10464911B2/en active Active
- 2016-07-27 BR BR112017027798-0A patent/BR112017027798B1/pt active IP Right Grant
-
2017
- 2017-10-24 PH PH12017501939A patent/PH12017501939B1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI694074B (zh) | 作為組蛋白去乙醯酶６抑制劑之１,３,４-㗁二唑磺醯胺衍生物及含彼之醫藥組合物 | |
| TWI639587B (zh) | 作為組蛋白去乙醯酶６抑制劑之１，３，４－二唑磺胺衍生物及含彼之醫藥組合物 | |
| TWI694073B (zh) | 作為組蛋白去乙醯酶６抑制劑之二唑胺衍生物及含彼之醫藥組合物 | |
| CN108026056B (zh) | 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑酰胺衍生物化合物及其药物组合物 | |
| TWI694075B (zh) | 作為組蛋白去乙醯酶６抑制劑之１,３,４-㗁二唑衍生物及含彼之醫藥組合物 | |
| CN106232584A (zh) | 作为组蛋白脱乙酰酶6抑制剂的新型化合物和包含其的药物组合物 | |
| CN104822653B (zh) | N‑丙‑2‑炔基甲酰胺衍生物及其作为trpa1拮抗剂的用途 | |
| TWI617545B (zh) | 作為選擇性組織蛋白去乙醯酶抑制劑之雜環烷基衍生物化合物及包含其之醫藥組合物 | |
| CN113924296A (zh) | 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑衍生化合物及包含其的药物组合物 | |
| TWI770841B (zh) | 作為組蛋白脫乙醯基酶６抑制劑之1,3,4-㗁二唑衍生物化合物及包含其的醫藥組合物 | |
| TWI844004B (zh) | 二唑硫羰基化合物及包含該等化合物之醫藥組合物 | |
| TWI786553B (zh) | 二唑衍生物化合物及包含其的醫藥組合物 | |
| TWI807300B (zh) | 二唑衍生物化合物及包含其的藥物組合物 | |
| HK1251549B (zh) | 作为组蛋白去乙醯酶6抑制剂的1，3，4-恶二唑磺醯胺衍生物及含其的医药组合物 | |
| HK40060493B (zh) | 作为组蛋白脱乙酰酶6抑制剂的1，3，4-恶二唑衍生化合物及包含其的药物组合物 | |
| HK40086988A (zh) | 作为组蛋白去乙酰酶6抑制剂的新化合物及包含该化合物的药物组合物 | |
| HK40074260B (zh) | 作为组蛋白脱乙醯酶6抑制剂的1，3，4-恶二唑衍生物化合物以及包含其的药物组合物 | |
| HK40060493A (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| HK40075698B (zh) | 作为组蛋白脱乙酰酶6抑制剂的1，3，4-恶二唑衍生物化合物以及包含其的药物组合物 | |
| HK1251571B (zh) | 作为组蛋白脱乙酰基酶6抑制剂的1，3，4-恶二唑磺酰胺衍生化合物及含有其的医药组合物 | |
| CN114945368A (zh) | N2-芳基甲基-4-卤代烷基-哒嗪-3-酮化合物及其用途 | |
| HK1251939B (zh) | 作为组蛋白脱乙酰酶6抑制剂的1,3,4-恶二唑酰胺衍生物化合物及其药物组合物 | |
| HK1259897B (zh) | 作为组蛋白脱乙酰基酶6抑制剂的恶二唑胺衍生物化合物及包含所述化合物的药物组合物 | |
| HK1259897A1 (en) | Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| HK1227394B (zh) | 作为组蛋白脱乙酰酶6抑制剂的新型化合物和包含其的药物组合物 |